Browse the evidence

Lessened emotional eating is significantly associated with concurrent reductions in weight and waist circumference.

Reducing emotional eating can be an effective strategy for achieving weight loss and waist circumference reduction.

Median time to maintenance was significantly shorter for Tirzepatide (32 days) than Semaglutide (143 days).

Practitioners may prefer Tirzepatide for quicker dose optimization.

Obesity medications (OMs) produce meaningful weight loss (∼5%-24%) and improve cardiometabolic health.

Practitioners can expect significant weight loss and health benefits from OMs.

Advanced pharmacotherapy with GLP-1 receptor agonists can achieve 15%–20% weight loss.

Clinicians can consider GLP-1 receptor agonists as an effective pharmacotherapy option for weight loss.

Bariatric and metabolic surgery is more effective than medicinal treatment for reversing NASH and improving liver fibrosis.

Practitioners should consider bariatric surgery as a treatment option for patients with NASH who are also obese and have type 2 diabetes.

Weight loss of at least 10% is required to achieve meaningful clinical remission rates in NASH.

Weight management strategies should aim for at least a 10% reduction in body weight for patients with NASH.

Recent antiobesity drugs have shown weight loss effects of 12%–17% and can resolve NASH in some patients.

Consider the use of antiobesity medications as part of a comprehensive treatment plan for NASH.

At 15 months, total body weight loss (TBWL) was greater in mild versus severe IMS groups (14.8% vs. 11.0%, p = 0.015).

Clinicians should consider IMS severity when predicting weight loss outcomes with tirzepatide.

The proportion achieving ≥ 20% TBWL was nearly two-fold higher in mild versus severe IMS (27% vs. 14%, p = 0.03).

Higher IMS severity is associated with lower chances of achieving significant weight loss with tirzepatide.

Obesity management requires a long-term multimodal strategy that incorporates individualized treatment goals.

Practitioners should develop personalized management plans for obesity that consider individual goals and interventions.

Tirzepatide has demonstrated superior efficacy in promoting weight loss and maintaining a healthy body weight compared to traditional incretin therapies.

Tirzepatide may be a more effective option for weight management in patients with obesity.

Dual agonists improve glycemic control and promote substantial weight loss.

Practitioners can consider dual agonists as effective options for improving glycemic control and aiding weight loss in patients with metabolic diseases.

Baseline metabolic health predicts weight-loss outcomes and recurrence risk.

Assessing baseline metabolic health can guide individualized treatment plans for bariatric surgery patients.

The nutritional guidance-only group experienced the most pronounced reduction in body mass.

Nutritional guidance alone can lead to significant weight loss in overweight and obese women.

WB-EMS, Pilates, and Yoga are associated with a reduced loss of muscle mass during diet-induced weight loss.

Including exercises like WB-EMS, Pilates, or Yoga can help maintain muscle mass while losing weight.

Phase 3 clinical trials showed superior efficacy of tirzepatide compared to existing pharmacotherapies, reaching body weight reductions of approximately 22.5% and hemoglobin A1c (HbA1c) reductions of up to 2.4 percentage points.

Tirzepatide may be a more effective treatment option for weight loss and glycemic control in patients with obesity and T2DM.

Phase 2 trials of retatrutide revealed weight reductions approaching 24.2% over 48 weeks.

Retatrutide may offer substantial weight loss benefits for individuals with obesity over a 48-week period.

Antiobesity drugs can lead to a mean total body weight loss of 10% to nearly 20% at high dosages.

Antiobesity medications can be effective for weight loss in specific patient populations.

LIGHT 2 is a seamless, adaptive phase 2b/3 trial evaluating the efficacy and safety of efsubaglutide alfa for chronic weight management in adults with overweight or obesity.

This trial aims to provide evidence on the effectiveness of efsubaglutide alfa for weight management.

The primary efficacy endpoint is percentage change in body weight.

The trial will measure how effective efsubaglutide alfa is at reducing body weight.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 10.10 points in the IWQOL-Lite-CT physical function subscale.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

The guidelines provide context-specific recommendations tailored to individual patient needs.

Healthcare providers should customize obesity management strategies for individual patients.

The guidelines include recommendations for situations with limited resources.

Providers in resource-limited settings can utilize these guidelines to optimize care.

Once-monthly maridebart has produced clinically meaningful weight loss of approximately 12–16% in adults without diabetes and 8–12% in those with type 2 diabetes.

Practitioners can expect significant weight loss outcomes with once-monthly maridebart in their patients.